We have observed
3 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after May 1, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
A method for detecting a genetic predisposition to large intestine cancer (CRC)
A method for detecting a genetic predisposition to prostate cancer (PC)
Oligonucleotides, use thereof, methods and a kit for detection of DNA Borrelia burgdorferi, Bartonella henselae, Babesia divergens, Anaplasma phagocytophilum